HeartBeam Announces Commercial Partnership With ClearCardio for Cardiac Prevention Programs

HeartBeam has announced a commercial partnership with ClearCardio, a preventive cardiology practice serving thousands of patients through heart health screening and personalized prevention programs. ClearCardio will serve as HeartBeam's first commercial customer and plans to make an investment in the company, underscoring strategic alignment between the organizations. The staged rollout will integrate HeartBeam's synthesized 12-lead ECG technology into ClearCardio's cardiac prevention program for arrhythmia assessment, enabling patients to capture clinical-grade ECG readings from home using HeartBeam's patented cable-free 3D ECG system.

This partnership represents a significant milestone in making advanced cardiac monitoring accessible outside traditional medical facilities. The agreement, structured as a Letter of Intent outlining subscription-based commercial terms and a collaborative deployment plan, supports HeartBeam's broader growth strategy including expansion into concierge care and preventive cardiology networks. The technology integration addresses a critical need in cardiac care by allowing physicians to identify cardiac health trends and acute conditions while patients remain in their homes, potentially transforming how cardiac conditions are detected and monitored.

HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to technology enablement, creating what it describes as the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence.

The commercial partnership with ClearCardio comes as HeartBeam continues development of its 12-lead ECG patch monitor and advancement of its AI-driven cardiac care initiatives. The latest news and updates relating to BEAT are available in the company's newsroom at https://ibn.fm/BEAT. Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer. The collaboration represents a practical application of remote cardiac monitoring technology that could significantly impact preventive cardiology by enabling earlier detection and intervention for cardiac conditions.